GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study:

• This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
• This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2025–2030)
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global GM1 gangliosidosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
• The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Detailed Segmentation:

• Global GM1 Gangliosidosis Treatment Market, By Product Type :
  • LYS-GM101
  • PBGM01
  • AXO-AAV-GM1
• Global GM1 Gangliosidosis Treatment Market, By Disease Type :
  • Type 1 GM1 Gangliosidosis
  • Type 2 GM1 Gangliosidosis
  • Type 3 GM1 Gangliosidosis
• Global GM1 Gangliosidosis Treatment Market, By Region:
  • North America
    • By Product Type:
      • LYS-GM101
      • PBGM01
      • AXO-AAV-GM1
    • By Disease Type :
      • Type 1 GM1 Gangliosidosis
      • Type 2 GM1 Gangliosidosis
      • Type 3 GM1 Gangliosidosis
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Product Type:
      • LYS-GM101
      • PBGM01
      • AXO-AAV-GM1
    • By Disease Type :
      • Type 1 GM1 Gangliosidosis
      • Type 2 GM1 Gangliosidosis
      • Type 3 GM1 Gangliosidosis
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Rest of World
    • By Product Type:
      • LYS-GM101
      • PBGM01
      • AXO-AAV-GM1
    • By Disease Type :
      • Type 1 GM1 Gangliosidosis
      • Type 2 GM1 Gangliosidosis
      • Type 3 GM1 Gangliosidosis
    • By Region:
      • Latin America
      •  Asia Pacific
      •  Middle East
      • Africa.
• Company Profiles.
  • Axovant Gene Therapies Ltd. *
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Passage Bio
  • Lyosgene

 “*” marked represents similar segmentation in other categories in the respective section.